No Data
Bidwell Pharmaceuticals (688073.SH): Plans to spend 50 million to 0.1 billion yuan to repurchase shares.
On February 7, Gelonghui reported that Bid Pharma (688073.SH) announced that the company's repurchased shares are intended to be used for the company's Stock-based Incentive or employee stock ownership plan at a suitable time in the future. The amount for repurchased shares shall not be less than 50 million yuan (inclusive) and shall not exceed 100 million yuan (inclusive), with the repurchase price not exceeding 72.30 yuan per share (inclusive). Recently, the company obtained a "Loan Commitment Letter" issued by CM BANK Shanghai Branch, agreeing to provide special loan support for the repurchase of the company's shares, with the maximum special loan amount not exceeding 90 million yuan and a term of 36.
Bide Pharmatech to Issue Share to Acquire Assets
Gelonghui Announcement Highlights | Guangxi Liugong Machinery: Net income is expected to increase by 45%-70% in 2024; Zhaocai News: No business cooperation relationship has been established with Huandian Algo.
【Hot Topics】Senba Sensing Technology (300701.SZ): The actual controller and Chairman have been placed under control. Zhuochuang News (301299.SZ): No business cooperation relationship has been established with Huanfang Algo. Hainan Airlines Holding (600221.SH): Plans to dispose of 9 B787-8 airplanes. 【Project Investment】SH PHARMA (601607.SH): Plans to invest 1 billion yuan to establish a merger and acquisition Fund. Tofflon Science and Technology Group (300171.SZ): Plans to jointly invest with professional Institutions to establish a Shanghai Biomedical merger and acquisition Fund. 【Contract Winning】Beijing SOJO Electric (300444.SZ): Won a bid for 0.366 billion yuan for a South China Power Grid project.
Bid Medicine disclosed a "three-step" acquisition plan: specific transaction prices are not determined, planning to raise funds through a private placement.
① Regarding the purpose of the Trade, Bid Medicine stated that it can further improve Overseas sales channels, enhance the diversity of company products, and optimize the efficiency of the Global supply chain and warehousing Operation; ② Combi's Net income in the past two years was 22.0418 million USD and 20.4237 million USD. After the Trade is completed, Combi will be included in the management and consolidation scope of Bid Medicine.
Bidder Pharmaceutical (688073.SH): Continued suspension of trading.
Gelonghui, January 20th丨Bidet Pharmaceutical (688073.SH) announced that the company is planning to acquire control of Zhuhai Weibo Investment Co., Ltd. by issuing shares to Weiwu (Suzhou) Health Industry Investment Fund (Limited Partnership) and Vivo CypressX, Co. Limited, while also proposing to raise matching funds. According to the relevant regulations of the Shanghai Stock Exchange, after the company's application, the company's Stocks will be suspended from trading starting from January 14, 2025 (Tuesday), with the original estimated suspension period not exceeding 5 trading days. As of the date of this announcement, all related parties are actively.
Bide Pharmatech Investing $103 Million in Zhuhai Vivo Investment JV
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
